Progyny, Inc. (PGNY)
Healthcare · NMS · US
Price as at 30 Sept 2026, 23:36 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Progyny, Inc. trades at $25.19, which is 41% below the $35.42 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 40 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 27.2 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
PGNY earnings and analyst estimates
Recommendation mix, 12 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
PGNY passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$51.48M · 0.0% of book
- Baillie Gifford, BAILLIE GIFFORD & CO$31.10M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$22.99M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$12.67M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$12.24M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in PGNY
Trades in PGNY disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 30 Jul 2020 · disclosed 19 Aug 2020
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 30 Jun 2020 · disclosed 17 Jul 2020
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 1 Jun 2020 · disclosed 16 Jun 2020
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 21 May 2020 · disclosed 16 Jun 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
PGNY peers
The largest companies in the same industry (Healthcare Plans), then in the same sector.
- UNH UnitedHealth Group Incorporated
- CVS CVS Health Corporation
- MOH Molina Healthcare, Inc.
- OSCR Oscar Health, Inc.
- CLOV Clover Health Investments, Corp.
- MRAI Marpai, Inc.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Progyny, Inc. (PGNY) undervalued?
Against our fair value estimate of $35.42, PGNY at $25.19 is 41% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own PGNY?
13 of the institutions we track reported a position in PGNY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is PGNY's P/E ratio?
PGNY trades at 27.2 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
When does PGNY report earnings next?
Progyny, Inc. is scheduled to report on 5 Nov 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its PGNY data?
Fundamentals for PGNY come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 23:36 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for PGNY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.